Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Rezolute (RZLT) Long-Term Debt Issuances (2012 - 2018)

Rezolute recorded quarterly Long-Term Debt Issuances of $4.1 million in Q2 2018, up 491.43% quarter-over-quarter from $700000.0 in Q1 2018.

Rezolute's Long-Term Debt Issuances history runs 4 years deep, the most recent figure standing at $4.1 million for Q2 2018.

  • In Q2 2018, Long-Term Debt Issuances changed N/A year-over-year to $4.1 million; the TTM figure through Jun 2019 stood at $4.8 million (changed 0.0% YoY), while the FY2018 annual figure was $5.3 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $4.1 million for Q2 2018 at Rezolute, up from $700000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $4.1 million in Q2 2018 to a low of -$1.2 million in Q1 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Rezolute 374.41 Mn 374.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2018 4.14 Mn
Jun 30, 2018 4.14 Mn
Mar 31, 2018 700,000.00
Mar 31, 2018 700,000.00
Jun 30, 2014 2.47 Mn
Jun 30, 2014 2.47 Mn
Mar 31, 2014 -1.19 Mn
Mar 31, 2014 -1.19 Mn
Dec 31, 2013 1.42 Mn
Dec 31, 2013 1.42 Mn
Mar 31, 2013 125,000.00
Mar 31, 2013 125,000.00
Dec 31, 2012 700,000.00
Dec 31, 2012 700,000.00
Sep 30, 2012 750,000.00
Sep 30, 2012 750,000.00
Jun 30, 2012 845,000.00
Jun 30, 2012 845,000.00
Mar 31, 2012 1.20 Mn
Mar 31, 2012 1.20 Mn